Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity
Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity
Patients with immune thrombocytopenia (ITP) commonly have antiplatelet antibodies that cause thrombocytopenia through Fcγ receptors (FcγRs). Antibodies specific for FcγRs, designed to inhibit antibody-FcγR interaction, had been shown to improve ITP in refractory human patients. However, the development of such FcγR-specific antibodies has stalled because of adverse events, a phenomenon recapitulated in mouse models. One hypothesis behind these adverse events involved the function of the Fc region of the antibody, which engages FcγRs, leading to inflammatory responses. Unfortunately, inhibition of Fc function by deglycosylation failed to prevent this inflammatory response. In this work, we hypothesize that the bivalent antigen-binding fragment regions of immunoglobulin G are sufficient to trigger adverse events and have reasoned that designing a monovalent targeting strategy could circumvent the inflammatory response. To this end, we generated a fusion protein comprising a monovalent human FcγRIIIA-specific antibody linked in tandem to human serum albumin, which retained FcγR-binding activity in vitro. To evaluate clinically relevant in vivo FcγR-blocking function and inflammatory effects, we generated a murine version targeting the murine FcγRIII linked to murine albumin in a passive murine ITP model. Monovalent blocking of FcγR function dramatically inhibited antibody-dependent murine ITP and successfully circumvented the inflammatory response as assessed by changes in body temperature, basophil activation, and basophil depletion. Consistent with our hypothesis, in vivo cross-linking of the fusion protein induced these inflammatory effects, recapitulating the adverse events of the parent antibody. Thus, monovalent blocking of FcγR function demonstrates a proof of concept to successfully treat FcγR-mediated autoimmune diseases.
132-138
Yu, Xiaojie
44d52374-eacc-4e23-b7da-c881e6d3a5dd
Menard, Melissa
199dda93-7705-43b9-a96d-3dfcde6a92a0
Prechl, Jozsef
0679fd22-f620-4d8b-a85f-d1e3946bb02d
Bhakta, Varsha
d5fc6e99-9f8d-4d03-aa6f-a26e5c5d5a24
Sheffield, William P.
296629d7-61fe-4185-ae6a-3a76f0e54fdf
Lazarus, Alan H.
eecf3844-9875-4fc1-b9a7-b6d26bcb0758
7 January 2016
Yu, Xiaojie
44d52374-eacc-4e23-b7da-c881e6d3a5dd
Menard, Melissa
199dda93-7705-43b9-a96d-3dfcde6a92a0
Prechl, Jozsef
0679fd22-f620-4d8b-a85f-d1e3946bb02d
Bhakta, Varsha
d5fc6e99-9f8d-4d03-aa6f-a26e5c5d5a24
Sheffield, William P.
296629d7-61fe-4185-ae6a-3a76f0e54fdf
Lazarus, Alan H.
eecf3844-9875-4fc1-b9a7-b6d26bcb0758
Yu, Xiaojie, Menard, Melissa, Prechl, Jozsef, Bhakta, Varsha, Sheffield, William P. and Lazarus, Alan H.
(2016)
Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity.
Blood, 127 (1), .
(doi:10.1182/blood-2015-08-664656).
Abstract
Patients with immune thrombocytopenia (ITP) commonly have antiplatelet antibodies that cause thrombocytopenia through Fcγ receptors (FcγRs). Antibodies specific for FcγRs, designed to inhibit antibody-FcγR interaction, had been shown to improve ITP in refractory human patients. However, the development of such FcγR-specific antibodies has stalled because of adverse events, a phenomenon recapitulated in mouse models. One hypothesis behind these adverse events involved the function of the Fc region of the antibody, which engages FcγRs, leading to inflammatory responses. Unfortunately, inhibition of Fc function by deglycosylation failed to prevent this inflammatory response. In this work, we hypothesize that the bivalent antigen-binding fragment regions of immunoglobulin G are sufficient to trigger adverse events and have reasoned that designing a monovalent targeting strategy could circumvent the inflammatory response. To this end, we generated a fusion protein comprising a monovalent human FcγRIIIA-specific antibody linked in tandem to human serum albumin, which retained FcγR-binding activity in vitro. To evaluate clinically relevant in vivo FcγR-blocking function and inflammatory effects, we generated a murine version targeting the murine FcγRIII linked to murine albumin in a passive murine ITP model. Monovalent blocking of FcγR function dramatically inhibited antibody-dependent murine ITP and successfully circumvented the inflammatory response as assessed by changes in body temperature, basophil activation, and basophil depletion. Consistent with our hypothesis, in vivo cross-linking of the fusion protein induced these inflammatory effects, recapitulating the adverse events of the parent antibody. Thus, monovalent blocking of FcγR function demonstrates a proof of concept to successfully treat FcγR-mediated autoimmune diseases.
Text
2015-Monovalent Fc receptor blockade by an anti–Fcγ receptor_albumin fusion protein ameliorates murine ITP with abrogated toxicity
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Accepted/In Press date: 18 October 2015
e-pub ahead of print date: 23 October 2015
Published date: 7 January 2016
Identifiers
Local EPrints ID: 436964
URI: http://eprints.soton.ac.uk/id/eprint/436964
ISSN: 0006-4971
PURE UUID: c2d7d7ac-3179-4409-bd11-ed7b93947d03
Catalogue record
Date deposited: 14 Jan 2020 17:34
Last modified: 16 Mar 2024 05:57
Export record
Altmetrics
Contributors
Author:
Xiaojie Yu
Author:
Melissa Menard
Author:
Jozsef Prechl
Author:
Varsha Bhakta
Author:
William P. Sheffield
Author:
Alan H. Lazarus
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics